Bristol-Myers (BMY), Pfizer (PFE) Tick Higher; ELIQUIS NDA Accepted for Review
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Join SI Premium – FREE
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) are trading a little higher early Tuesday, following reports that the U.S. FDA accepted a New Drug Application (NDA) for ELIQUIS (apixaban) for review.
Bristol is up about 0.4 percent, while Pfizer is 1 percent stronger.
Click here for more.
Bristol is up about 0.4 percent, while Pfizer is 1 percent stronger.
Click here for more.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- FDA grants Nuvation Bio fast track status for brain cancer drug
- Harrow study shows Iheezo cuts discomfort after eye injections
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
